| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target is the bacterial 50S ribosomal subunit. Carbomycin B binds to the 50S subunit, inhibiting protein synthesis by blocking the translocation step of peptide chain elongation and preventing the release of peptidyl-tRNA. This leads to inhibition of bacterial protein synthesis and growth arrest. Its activity is not significantly affected by the presence of human serum or by different laboratory media.
|
|---|---|
| ln Vitro |
In vitro, Carbomycin B is active against Gram-positive bacteria and some Gram-negative organisms including Neisseria catarrhalis and Haemophilus influenzae. It is primarily bacteriostatic. MIC values are determined against susceptible bacterial strains using standard broth microdilution methods. Its activity is not significantly affected by human serum or different laboratory media.
|
| ln Vivo |
No specific in vivo efficacy data have been published for Carbomycin B in accessible literature. As a macrolide antibiotic, it may have applications in treating respiratory and soft tissue infections. Its pharmacokinetic parameters and toxicity profile are not well characterized. No animal efficacy studies have been published.
|
| Enzyme Assay |
No specific receptor binding or enzyme inhibition assays are established for Carbomycin B. Ribosome binding assays use radiolabeled erythromycin or other macrolide antibiotics and bacterial 50S ribosomal subunit preparations. Competition binding determines affinity and specificity for the ribosomal target.
|
| Cell Assay |
Antibacterial susceptibility testing uses broth microdilution methods against Gram-positive bacteria and selected Gram-negative organisms. Carbomycin B is incubated with bacterial cultures, and MIC values are determined by measuring growth inhibition after 18-24 hours. Bacteriostatic versus bactericidal activity is assessed by MBC determination.
|
| Animal Protocol |
No specific animal protocols are established for Carbomycin B. General efficacy studies in animal models of bacterial infection could involve intraperitoneal or oral administration, followed by assessment of survival rates and bacterial burden in tissues. No published efficacy or safety studies are available.
|
| References |
| Molecular Formula |
C42H67NO15
|
|---|---|
| Molecular Weight |
825.99
|
| Exact Mass |
825.451
|
| CAS # |
21238-30-2
|
| PubChem CID |
6540453
|
| Appearance |
White to off-white solid
|
| Source |
Originated from microorganisms: Streptomyces halsfedii
|
| LogP |
3.221
|
| tPSA |
202.89
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
58
|
| Complexity |
1430
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
[C@@H]1(OC(C)=O)CC(=O)O[C@H](C)CC=CC=CC(=O)[C@H](C)C[C@H](CC=O)[C@H](OC(CC(C)C)=O)[C@H]1OC |t:12,14,&1:0,9,18,21,25,33|
|
| InChi Key |
ZRNXEMIDBIPJDC-HLPDZUSBSA-N
|
| InChi Code |
InChI=1S/C42H67NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29,31,34-41,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
|
| Chemical Name |
[(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,11E,13E,16R)-4-acetyloxy-5-methoxy-9,16-dimethyl-2,10-dioxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate
|
| Synonyms |
Magnamycin B; Carbomycin B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2107 mL | 6.0533 mL | 12.1067 mL | |
| 5 mM | 0.2421 mL | 1.2107 mL | 2.4213 mL | |
| 10 mM | 0.1211 mL | 0.6053 mL | 1.2107 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.